Despite of COVID-19 challenging the routine of clinical trials worldwide, Global Clinical Trials has successfully randomized the first patient into a clinical trial evaluating the efficacy of IP in the sore throat pain relief.
This is a phase IV, multicenter, randomized, non-inferiority trial aiming to enroll over 300 patients globally.
The first patient was enrolled only 4 days after the site activation.
«We are honored to manage this clinical program in Russia and to be able to deliver FPI shortly after site initiation. At the same time, keeping patients, site and GCT staff safe is our ultimate focus. We are hoping the trial will be a success and will improve treatment options for patients in Eastern Europe,» said Eugene Selivra, MD, CEO of Global Clinical Trials.